1. Home
  2. APVO vs IBG Comparison

APVO vs IBG Comparison

Compare APVO & IBG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aptevo Therapeutics Inc.

APVO

Aptevo Therapeutics Inc.

HOLD

Current Price

$6.30

Market Cap

8.3M

Sector

Health Care

ML Signal

HOLD

IBG

Innovation Beverage Group Limited Ordinary Shares

HOLD

Current Price

$3.60

Market Cap

8.8M

ML Signal

HOLD

Company Overview

Basic Information
Metric
APVO
IBG
Founded
2016
2018
Country
United States
Australia
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Beverages (Production/Distribution)
Sector
Health Care
Consumer Staples
Exchange
Nasdaq
Nasdaq
Market Cap
8.3M
8.8M
IPO Year
N/A
2024

Fundamental Metrics

Financial Performance
Metric
APVO
IBG
Price
$6.30
$3.60
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
393.1K
140.6K
Earning Date
02-20-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.53
$3.27
52 Week High
$1,609.20
$49.25

Technical Indicators

Market Signals
Indicator
APVO
IBG
Relative Strength Index (RSI) 44.04 71.76
Support Level $6.88 $0.65
Resistance Level $7.84 $5.10
Average True Range (ATR) 0.69 0.34
MACD -0.54 0.38
Stochastic Oscillator 2.95 73.02

Price Performance

Historical Comparison
APVO
IBG

About APVO Aptevo Therapeutics Inc.

Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.

About IBG Innovation Beverage Group Limited Ordinary Shares

Innovation Beverage Group Ltd is a developer, manufacturer, marketer, exporter, and retailer of a growing beverage portfolio of 70 formulations across 14 alcoholic and non-alcoholic brands. The company's focus is on premium and super premium brands. The Group has two reportable geographic segments: Australia and the United States.

Share on Social Networks: